Drugs / DCC-2812
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06966024 | Aug 2025 → Feb 2029 expected | castration-resistant prostate carcinoma, renal cell carcinoma, urothelial carcinoma | Deciphera Pharmaceuticals, LLC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCC-2812 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06966024 ↗ |
| Action | Activate | “selective general control nonderepressible 2 (GCN2) activator DCC-2812” NCT06966024 ↗ |
| Route | Oral | “Administered orally” NCT06966024 ↗ |